Hospira announced the re-launch of Oxaliplatin for Injection, the generic version of Sanofi-AventisEloxatin.

Hospira originally launched Oxaliplatin for Injection in August 2009 and suspended sales at the end of June 2010 after settling a patent litigation with Sanofi, with the right to re-launch the product well in advance of patent expiry.

Oxaliplatin, an alkylating agent, is indicated as adjuvant treatment for Stage 3 colon cancer in patients who have undergone complete resection of the primary tumor (in combination with infusional 5-FU/LV) and for the treatment of advanced colorectal cancer (in combination with infusional 5-FU/LV).

Oxaliplatin for Injection will be available as a solution in 50mg and 100mg single-use vials.

For more information call (800) 615-0187 or visit http://www.hospira.com.